Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026
Same author

Imbalanced immune cell network and suboptimal cell activation: signatures associated with disease severity in vaccine-naïve COVID-19 patients.

Frontiers in immunology·2026
Same author

Age, sex, smoking-specific prevalence and progression in interstitial lung abnormality: patient-level meta-analysis.

Annals of the American Thoracic Society·2026
Same author

Utility of Z Scores for Defining Progressive Pulmonary Fibrosis in Interstitial Lung Disease.

Archivos de bronconeumologia·2026
Same author

Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions.

The European respiratory journal·2025
Same author

Preserving conceptual clarity: why hypersensitivity pneumonitis should remain a separate entity from bronchiolocentric interstitial pneumonia.

The European respiratory journal·2025

Related Experiment Video

Updated: May 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Idiopathic pulmonary fibrosis.

Talmadge E King1, Annie Pardo, Moisés Selman

  • 1Department of Medicine, University of California, San Francisco, CA 94143-0120, USA. tking@medicine.ucsf.edu

Lancet (London, England)
|July 2, 2011
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is an age-related lung disease. Current evidence suggests abnormally activated alveolar epithelial cells drive fibrosis, leading to lung scarring and destruction.

Area of Science:

  • Pulmonology
  • Pathogenesis of lung diseases
  • Age-related diseases

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a severe, age-related lung disease with limited treatments.
  • Previously considered inflammatory, IPF pathogenesis is now linked to activated alveolar epithelial cells (AECs).
  • AECs drive fibrosis by producing mediators that promote fibroblast/myofibroblast foci formation.

Purpose of the Study:

  • To review current understanding of IPF.
  • To discuss clinical course and therapeutic options for IPF.
  • To explore mechanisms underlying IPF pathogenesis, including aging and epithelial activation.

Main Methods:

  • Literature review of recent data on IPF.
  • Analysis of evidence linking aging, epigenetic changes, and aberrant epithelial activation to IPF.

Related Experiment Videos

Last Updated: May 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

  • Synthesis of information on clinical aspects and treatment strategies.

    • Main Results:

    • Fibrosis in IPF results from excessive extracellular matrix deposition, primarily collagens, by fibroblast and myofibroblast foci.
    • Abnormal recapitulation of developmental pathways and epigenetic alterations are implicated in IPF pathogenesis.
    • The precise mechanisms connecting aging, epithelial dysfunction, and IPF remain under investigation.

    Conclusions:

    • IPF pathogenesis involves complex interactions between aging, aberrant epithelial cell activation, and fibrotic processes.
    • Understanding these mechanisms is crucial for developing effective therapeutic strategies for IPF.
    • Further research is needed to elucidate the molecular pathways driving IPF and to identify novel treatment targets.